Literature DB >> 20558034

Two prognostic indicators of the publication rate of clinical studies were available during ethical review.

Jean Philippe de Jong1, Gerben Ter Riet, Dick Ludolf Willems.   

Abstract

OBJECTIVE: To identify prognostic indicators of the publication rate of clinical studies, available to research ethics committees (RECs) during review. STUDY DESIGN AND
SETTING: Retrospective survival study of a random sample of 100 studies, approved by a Dutch academic REC, with follow-up information by questionnaire and bibliographic searches. Multivariate Cox regression analysis of the association between publication rate and seven factors available during review: six study characteristics and the number of letters sent by the committee during review representing the length of the review process.
RESULTS: Two factors were associated with publication rate: studies with possible therapeutic benefit to participants were less likely to be published than nontherapeutic studies (adjusted hazard ratio [AHR]: 0.16; 95% confidence interval [CI]: 0.03-0.54); with every letter sent, publication was less likely (AHR: 0.46 per letter; 95% CI: 0.17-0.98). Possibly, studies with more-than-minimal burdens to participants were more likely to be published than studies with minimal burdens (AHR: 3.90, 95% CI: 1.03-16.64).
CONCLUSION: We identified two prognostic indicators of publication rate. After suitable replication, RECs might explore using prognostic indicators, such as these, to target study protocols at high risk for nonpublication. Discussing the risk of nonpublication with investigators could help prevent nonpublication.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20558034     DOI: 10.1016/j.jclinepi.2010.01.018

Source DB:  PubMed          Journal:  J Clin Epidemiol        ISSN: 0895-4356            Impact factor:   6.437


  7 in total

1.  Occurrence and determinants of selective reporting of clinical drug trials: design of an inception cohort study.

Authors:  Cornelis A van den Bogert; Patrick C Souverein; Cecile T M Brekelmans; Susan W J Janssen; Manon van Hunnik; Gerard H Koëter; Hubertus G M Leufkens; Lex M Bouter
Journal:  BMJ Open       Date:  2015-07-07       Impact factor: 2.692

2.  Extent of non-publication in cohorts of studies approved by research ethics committees or included in trial registries.

Authors:  Christine Schmucker; Lisa K Schell; Susan Portalupi; Patrick Oeller; Laura Cabrera; Dirk Bassler; Guido Schwarzer; Roberta W Scherer; Gerd Antes; Erik von Elm; Joerg J Meerpohl
Journal:  PLoS One       Date:  2014-12-23       Impact factor: 3.240

3.  Systematic review protocol assessing the processes for linking clinical trial registries and their published results.

Authors:  Rabia Bashir; Adam G Dunn
Journal:  BMJ Open       Date:  2016-10-03       Impact factor: 2.692

4.  Non-Publication Is Common among Phase 1, Single-Center, Not Prospectively Registered, or Early Terminated Clinical Drug Trials.

Authors:  Cornelis A van den Bogert; Patrick C Souverein; Cecile T M Brekelmans; Susan W J Janssen; Gerard H Koëter; Hubert G M Leufkens; Lex M Bouter
Journal:  PLoS One       Date:  2016-12-14       Impact factor: 3.240

5.  Publication bias in laboratory animal research: a survey on magnitude, drivers, consequences and potential solutions.

Authors:  Gerben ter Riet; Daniel A Korevaar; Marlies Leenaars; Peter J Sterk; Cornelis J F Van Noorden; Lex M Bouter; René Lutter; Ronald P Oude Elferink; Lotty Hooft
Journal:  PLoS One       Date:  2012-09-05       Impact factor: 3.240

6.  A Scoping Review of Empirical Research Relating to Quality and Effectiveness of Research Ethics Review.

Authors:  Stuart G Nicholls; Tavis P Hayes; Jamie C Brehaut; Michael McDonald; Charles Weijer; Raphael Saginur; Dean Fergusson
Journal:  PLoS One       Date:  2015-07-30       Impact factor: 3.240

Review 7.  Systematic review of the empirical evidence of study publication bias and outcome reporting bias - an updated review.

Authors:  Kerry Dwan; Carrol Gamble; Paula R Williamson; Jamie J Kirkham
Journal:  PLoS One       Date:  2013-07-05       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.